Document Type
Article
Embargo Period
1-1-1994
Publication Date
1-1-1994
Abstract
Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.
Journal
Journal of Experimental Medicine
Recommended Citation
Qin, Lihui; Chavin, Kenneth D.; Lin, Jixun; Yagita, Hideo; and Bromberg, Jonathan S., "Anti-CD2 Receptor and Anti-CD2 Ligand (CD48) Antibodies Synergize to Prolong Allograft Survival" (1994). MUSC Faculty Journal Articles. 103.
https://medica-musc.researchcommons.org/facarticles/103